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1 ABSTRACT 
Breath tests have been widely used in gastroenterology for several decades. The most 
well known test nowadays is perhaps the 
13
C-urea breath test for Helicobacter Pylori. 
Isotope-labelled breath test can, however, be applied in a wide range of conditions. The 
main aim of this thesis has been to determine the usefulness of 
13
C-labelled substances to 
diagnose small intestinal malabsorption. To this end, we have focused on coeliac patients, 
since coeliac disease is one of the most common causes of small intestinal malabsorption 
in the industrialised part of the world today. 
 The main objective of the first study of this thesis was to determine the 
diagnostic accuracy of the 13C-D-xylose breath test in diagnosis and follow-up of coeliac 
disease. Two cohorts of coeliac patients were reviewed retrospectively. In one cohort 
patients had been tested with a 14C-D-xylose breath test before and after gluten-free 
treatment (GFD). In the other patients had been tested with a 13C-D-xylose breath test 
before and after GFD. Results were similar in the two cohorts, and confirmed that the 
non-radioactive isotope 
13
C-D-xylose can replace the radioactive isotope 
14
C-D-xylose 
without loss of diagnostic accuracy. Furthermore, we developed a diagnostic index for 
the D-xylose breath tests in which 
13
CO2 or 
14
CO2 levels in breath at 30 minutes were 
combined with levels in breath at 210 minutes in a gas fraction index: 30 minutes 
value/210 minutes value. Using this diagnostic index, we found sensitivities of 84-95% 
and specificities of 87-94% with the two breath tests. After treatment with a gluten-free 
diet, most patients improved their gas fraction index, but did not reach the levels of 
healthy control subjects. 
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In the second study we compared the 
13
C-D-xylose breath test to measurements of 
D-xylose in plasma and urine in untreated coeliac patients and treated coeliac patients. 
Test sensitivity and specificity for coeliac disease versus healthy controls were 88% and 
84% with the 
13
C-D-xylose breath test, 65% and 71% with a 1-h plasma D-xylose test, 
and 55% and 74% with a 4-h urine D-xylose excretion test. Breath test results improved 
significantly in the treated coeliac group compared to untreated patients, but were not 
normalized compared to healthy control subjects. 
The aim of the two last studies was to develop a novel 
13
C-sorbitol breath test and 
determine the diagnostic accuracy of the test for coeliac disease. We performed a 
prospective study of coeliac patients who were tested at diagnosis before commencing on 
a gluten-free diet and after approximately one year on GFD. Coeliac patients were 
compared to a group of patients with similar gastrointestinal symptoms without coeliac 
disease and to healthy control subjects. All study subjects performed the H2-sorbitol 
breath test concomitant with the 
13
C-sorbitol breath test. We found that the 
13
C-sorbitol 
breath test duration could be shortened to one-hour without loss of diagnostic precision 
versus a four-hour test. We proposed a diagnostic algorithm to divide patients into high, 
moderate and low-risk groups for coeliac disease. 
13
C-sorbitol breath test results 
increased in treated coeliac patients, but did not reach levels of healthy control subjects. 
The H2-sorbitol breath test had unsatisfactory specificity versus control groups. 
We concluded that 
13
C-labelled breath tests are sensitive tools for small intestinal 
malabsorption. Further studies are needed to determine how 
13
C-labelled breath tests can 
be of value in follow-up of coeliac disease. 
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2 ABBREVIATIONS 
 
13
C-SBT 
13
C-sorbitol breath test 
GC  gas chromatography  
GFD  gluten-free diet 
GF-index gas fraction index 
HLA  human leukocyte antigen  
HPLC  high performance liquid chromatography  
H2-SBT H2-sorbitol breath test 
IEL  intraepithelial lymphocyte  
Ig  immunoglobulin 
IRMS  isotope ratio mass spectrometry 
tTGA  tissue-transglutaminase antibody  
SIBO  small intestinal bacterial overgrowth 
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3 INTRODUCTION 
 
3.1 Coeliac disease 
Coeliac disease is a chronic inflammatory disease of the small intestine induced by 
ingestion of proline-rich and glutamine-rich gluten proteins in wheat, rye and barley in 
genetically susceptible people [1]. The first description of the disease dates from the 1
st
 
and 2
nd
 centuries CE [2]. The disorder is characterized by a diverse clinical heterogeneity 
that ranges from asymptomatic to severely symptomatic. Patients with coeliac disease 
have increased morbidity due to the frequent association with autoimmune disorders [3-
9], and increased mortality resulting from the emergence of T-cell clonal proliferation 
that predispose the patient to enteropathy-type T-cell lymphoma [10-12]. A strict gluten-
free diet is the mainstay of safe and effective treatment. 
 
3.1.1 Genes and environment 
Coeliac disease is strongly linked with HLA-DQ genes. Most patients carry a variant of 
DQ2 and others carry a variant of DQ8 [13]. The association between HLA genes and 
coeliac disease is very strong compared with other HLA-linked diseases [14]. However, 
other non-HLA regions must be involved as well, since the concordance rate between 
HLA identical siblings is much lower than between monozygotic twins who show a 
concordance rate of 85% [15, 16]. 
Coeliac disease is induced in genetically susceptible people by gluten and possibly other 
environmental cofactors. Intestinal infections may be a trigger for coeliac disease, 
perhaps because an infection causes a transient rise in small-bowel permeability and 
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release of tissue transglutaminase that enhances gluten immunogenicity [17, 18]. Some 
drugs can enhance a person’s susceptibility to gluten - such as a course of interferon 
alpha [19]. Furthermore, infant-feeding practices and whether infants are introduced to 
dietary gluten while still being breastfed might affect the risk of developing coeliac 
disease [20, 21]. 
 
3.1.2 Pathophysiology 
After crossing the epithelium into the lamina propria, gluten peptides are deamidated by 
tissue transglutaminase and presented by DQ2+ or DQ8+ antigen-presenting cells to 
pathogenic CD4+ T cells. Activated CD4+ T cells drive a T-helper type 1 response that 
leads to the development of the coeliac lesion. The severity of the lesion - which can 
range from intraepithelial and lamina propria infiltration of inflammatory cells with 
normal architecture to crypt hyperplasia and varying degrees of villous atrophy to 
completely flat mucosa – can be graded by the Marsh classification, as modified by 
Oberhufer and colleagues [22]. 
 
 
3.1.3 Epidemiology 
The accuracy of estimates of the true prevalence of coeliac disease has been substantially 
improved by the increased reliability of serological tests. The IgA antigliadin antibodies 
used initially had low sensitivity and specificity [23-25], and the antiendomysial antibody 
test significantly improved the diagnostic accuracy. An important break-through came 
with the discovery that antiendomysial antibodies detect tissue transglutaminase [26]. 
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The IgA tissue transglutaminase antibody test used for screening of coeliac disease today 
has very high sensitivity and specificity for coeliac disease [27, 28]. By screening with 
serological tests, the prevalence of biopsy-proven coeliac disease in Finnish and Italian 
schoolchildren was reported to be 1:99 and 1:106, respectively [29, 30]. Similar rates of 
seroprevalence have been reported in adult populations in UK (1:87) and USA (1:105) 
[31, 32]. The highest rate of antiendomysial antibody positivity (5.6%) has been reported 
in Saharawi children [33].  
 
3.1.4 Clinical aspects 
Until the beginning of the 1980s, the use of intestinal biopsy was reserved for patients 
with overt malabsorption. Consequently, the prevalence of malabsorption among patients 
with coeliac disease was very high. As awareness of the disease improved and the 
threshold for investigation was lowered, more subtle forms of the disease and the variable 
clinical expression of the condition was acknowledged [1]. At the end of the 1980s- after 
the advent of serological tests - the number of patients with minor symptoms was twice 
the number of patients with overt malabsorption. There was a significant rise in the rate 
of diagnosis, and a reduction of the male to female ratio [34]. Coeliac disease is two to 
three times more common in women than in men, but this predominance falls after the 
age of 65 years.  
The factors that determine the severity of symptoms at presentation are not known. 
Neither the degree of duodenal villous atrophy nor the extent of visible enteropathy 
assessed by capsule endoscopy correlates with clinical presentation [35, 36]. 
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3.2 Breath analysis in gastroenterology 
The first gastroenterological applications of breath analysis were carried out by the 
medical student Charles Dodds in 1920 [37, 38]. He reported that the pressure of carbon 
dioxide (PC02) in breath rose after meals, and that the rise in PCO2 differed in patients 
with pernicious anaemia and pancreatic disease from healthy controls. Following these 
pioneering efforts, the area remained dormant until, in the 1960s, new techniques were 
developed simplifying the assessment of 
14
CO2 after administration of 
14
C-labeled 
compounds and of hydrogen (H2) after administration of carbohydrate [39]. 
 
3.2.1 
14
C-breath tests and 
13
C-breath tests 
Recovery of 
14
CO2 in breath after administration of 
14
C-labeled compounds indicates that 
metabolism of the radioactively labelled compound has occurred. When the rate-limiting 
step in the metabolism of the compound is intestinal absorption, measurement of breath 
14
CO2 output after oral administration of the compound may provide information about 
it’s rate of absorption. If the compound is metabolized solely by intestinal bacteria 
measurement of breath 
14
CO2 output after oral administration of the compound may 
provide information about the exposure of the compound to intestinal bacteria. 
The original radiospirometric studies applied to gastroenterological studies were 
performed by Schwabe et al., who administered 
14
C-labeled trioctanoate and monitored 
breath 
14
CO2 [40]. Cozetto el al., in 1964, applied the same technique to study intestinal 
absorption of fatty acids, glucose and lactose in children [41]. 
Tests in which breath 
14
CO2 is measured require the administration of small amounts of 
14
C-labeled compounds. The calculated radiation dose is extremely small. Nevertheless, 
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the tests should not be performed in children or pregnant women. When 
13
C-compounds 
became widely available at a reasonable cost and methods to measure 
13
C abundance in 
samples of CO2 were developed, 
14
C-labeled substrates were gradually replaced by non-
radioactive 
13
C-labeled substrates [42-45].  
The 
13
C-urea breath test for the diagnosis of Helicobacter Pylori infection is the 
most used stable isotope breath test in gastroenterology today [46, 47]. However, a range 
of substrates and functions can be monitored by means of 
13
C-breath tests [48, 49]. The 
underlying concept of the 
13
C-breath test is simple and similar to the 
14
C-breath tests: 
13
C 
is introduced into one or more functional groups in a substrate. The functional groups are 
linked to the rest of the molecule through bonds that are cleaved by specific enzymes. 
Once cleavage occurs, the functional group is further oxidized until CO2 is produced and 
excreted in breath.  
In 1978, Toskes et al. developed a new 
14
C-D-xylose breath test [50]. In a series 
of studies they showed that the 
14
C-D-xylose breath test was well suited to detect small 
intestinal bacterial overgrowth (SIBO) [51-53].  The test was later replaced by the 
13
C-D-
xylose breath test [54, 55]. However, the initial optimism regarding the utility of the 
14
C-
D-xylose and 
13
C-D-xylose breath tests for SIBO has been challenged by several studies 
showing less convincing results [56-58].  
 
3.2.2 Hydrogen breath tests 
In 1975, Newcomer et al., demonstrated the superiority of H2 measurements to 
14
CO2-
labelled lactose and blood sugar changes in detecting lactose malabsorption [59]. The H2-
lactose breath test has been shown to have high sensitivity for lactose malabsorption in 
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many repeated studies since then, and is accepted as the method of choice for lactose 
malabsorption by many gastroenterologists [60-63]. 
Soon after the introduction of the H2-lactose breath test, the H2-breath test was also 
applied to other complex sugars like fructose [64, 65], maltose [66], sucrose [67], sorbitol 
[68], and lactulose [69, 70]. In 1988, Corazza et al., presented a sorbitol H2-breath test for 
coeliac disease [71]. The initial study as well as follow-up studies demonstrated high 
sensitivity of the H2-sorbitol breath test for untreated coeliac disease [72, 73]. 
All cells produce CO2 during metabolism, but only bacteria can produce H2 and 
methane (CH4) as metabolic by-products. An increase in H2 concentration in breath after 
ingestion of a carbohydrate shows that bacterial fermentation of the carbohydrate has 
taken place in the intestine [74]. It has been shown that a relationship exists between H2 
and CH4 production, in which methanogenic bacteria are able to convert H2 to CH4, and 
this exchange occurs in the colon [75, 76].  A significant proportion of humans have a 
methanogenic gut bacterial flora [77-80]. Therefore, when intestinal bacteria metabolize 
carbohydrates, sometimes only H2 is produced, sometimes both H2 and CH4 appears in 
the exhaled air, and sometimes only CH4 will be increased. Methane should also be 
measured in breath tests for carbohydrate malabsorption in order to allow correct 
interpretation of the test. The response to a challenge-dose of sugar is measured from the 
pre-dose baseline or the lowest level reached prior to an increase.  
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3.3 D-xylose testing in malabsorption 
Absorption of D-xylose has been a gold standard test in the evaluation of small intestinal 
malabsorption since the 1960s [81, 82]. However, the diagnostic accuracy of the test has 
been subject to much controversy in later years [83-87]. D-xylose is a five carbon 
monosaccharide found naturally in plants [88]. The sugar is incompletely absorbed, 
which allows it to be used as an absorptive test [89]. The mechanism of D-xylose 
absorption in the small intestine is disputed. Data from intestinal perfusion studies in 
normal humans support predominantly passive absorption, transcellular or paracellular, 
with little or no carrier-mediated transport [90]. D-xylose is absorbed unchanged from the 
small intestine [91, 92]. Approximately 30% is metabolized by the liver to CO2 and 
threitol [93, 94]. Five percent is excreted unchanged in the bile and undergoes 
enterohepatic cycling [95], and the remainder is excreted in the urine.  
Normal subjects absorb approximately 70% of a 25g oral dose of D-xylose [96]. The 
absorption constant for D-xylose correlates closely with the 1-h serum concentration of 
D-xylose, and the 5-h urine content of D-xylose correlates closely with it’s absolute 
bioavailability [97]. Essentially all of the absorption, metabolism, and excretion occur 
within the first five hours after administration. 
From the 1960s and onwards a range of studies was performed which showed that a 5-h 
urine excretion test with 25g D-xylose distinguished clearly between normal individuals 
and patients with proximal intestinal malabsorption [98-110]. To improve the sensitivity, 
specificity and ease of D-xylose testing, various modifications of dosing and the 
inclusion of serum analyses have been suggested. Most studies have used the 25g or 5g 
D-xylose absorption test with either 5-h urine collection and/or 1-h serum levels. In 
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paediatrics, the 1-h serum level after 5g of D-xylose has been the preferred test due to the 
difficulty of collecting urine accurately in children [111-116].  
Other factors than malabsorption may affect the result of the D-xylose test and must be 
considered in clinical practice. The excretion of D-xylose in urine is dependent on its 
renal clearance, and renal insufficiency complicates the interpretation of the test [117, 
118]. Interpretation of D-xylose tests in geriatric patients must therefore take status of 
renal function into account [119-121]. Delayed gastric emptying may alter the absorption 
kinetics and give low 1-h serum levels [122].  
The 25g D-xylose H2-breath test was developed as an alternative to urine and serum 
analysis of D-xylose. This is an indirect test of D-xylose malabsorption, in which a rise in 
H2 signals that unabsorbed D-xylose has been delivered to the colon and metabolized by 
enteric bacteria. The H2-breath test circumvents some of the problems with the traditional 
D-xylose tests such as dependence on renal clearance and accurate urine collection. H2 
production after a 25g D-xylose dose was first shown to be well correlated with 5-h D-
xylose excretion and 90-min D-xylose levels in serum in tropical sprue [123].  Similar 
results were found when H2-breath testing was compared with 5-h urinary D-xylose for 
patients with various malabsorptive disorders [124]. One study showed that the 25g D-
xylose H2-breath test was more reliable in diagnosing coeliac disease than the 5-h urine 
D-xylose content [125]. Isotope-labelled breath tests with D-xylose have been evaluated 
for small intestinal bacterial overgrowth, but not for coeliac disease or other 
malabsorptive states.  
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3.4 Summary of introduction 
Coeliac disease is a small intestinal enteropathy that can develop in genetically disposed 
individuals upon exposure to gluten. Before the development of serological tests for 
coeliac disease and easy access to endoscopic procedures, malabsorption testing played a 
pivotal role in the diagnosis of coeliac disease. D-xylose testing was the most commonly 
used malabsorptive test. Initially D-xylose measurements were made in serum and urine, 
but in later years the D-xylose H2-breath test was developed as an alternative.  
Isotope-labelled breath tests have been much used in gastroenterology, but not as primary 
tests of coeliac disease or other malabsorptive states. 
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4 AIM OF THE STUDY 
 
The aim of this thesis has been to evaluate isotope-labelled breath tests as diagnostic tools 
in small intestinal malabsorption. We chose to focus on coeliac disease; the most frequent 
cause of small intestinal malabsorption in the Western world today. 
 
The specific aims of the present study were: 
 
1. To determine the diagnostic accuracy of the 
13
C-xylose breath test in diagnosis 
and follow-up of coeliac disease. 
2. To compare the 
13
C-xylose breath test with xylose absorption tests based on D-
xylose measurements in blood and urine. 
3. To develop a novel 
13
C-sorbitol breath test and determine the diagnostic accuracy 
of this test in diagnosis and follow-up of coeliac disease. 
4. To compare the 
13
C-sorbitol breath test with the conventional H2-sorbitol breath 
test. 
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5.1 Paper I 
The aim of the study was to evaluate the diagnostic properties of the 
13
C-D-xylose breath 
test and the 
14
C-D-xylose breath test in coeliac disease and develop a diagnostic breath 
test index.  
 Data from 41 patients with untreated coeliac disease who had performed the 
14
C-
D-xylose breath test, and 60 patients with untreated coeliac disease who had performed 
the 
13
C-D-xylose breath test were reviewed retrospectively. All patients in the 
14
C-D-
xylose breath test cohort repeated the breath test on a gluten-free diet (GFD), and 37 
patients in the 
13
C-D-xylose breath test cohort repeated the breath test on GFD. Patients 
were compared to a healthy control group. 
For both breath tests, combining breath test values at 30 minutes and 210 minutes 
(the gas fraction (GF) index: 30 min/210 min) resulted in the highest diagnostic accuracy. 
The breath tests had very similar diagnostic properties for untreated coeliac disease, with 
sensitivities of 84-95% and specificities of 87-94%. 
After treatment with a gluten-free diet, most patients improved their GF-index, 
but did not reach the levels of healthy controls. 
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5.2 Paper II 
The aim of this study was to compare the 
13
C-D-xylose breath test with D-xylose 
measurements in plasma and urine in a retrospective cohort of patients with coeliac 
disease. Data from 91 untreated coeliac patients, and 98 treated coeliac patients, who had 
performed the 
13
C-D-xylose breath test were evaluated. 1-h plasma D-xylose had been 
measured in 48 untreated and 41 treated coeliac patients. 4-h urine D-xylose excretion in 
urine had been measured in 47 untreated and 51 treated patients. Patients were compared 
to a healthy control group (n = 43). 
 Test sensitivity and specificity for coeliac disease versus healthy controls were 
88% and 84% with the 
13
C-D-xylose breath test, 65% and 71% with the 1-h plasma D-
xylose test, and 55% and 74% with the 4-h urine D-xylose excretion test. Breath test 
results improved significantly in the treated coeliac group compared to untreated patients, 
but were not normalized compared to healthy control subjects. No difference was found 
between D-xylose levels in plasma and urine between treated coeliac patients and healthy 
control subjects. 
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5.3 Paper III 
The aim of this study was to examine the diagnostic properties of a novel 
13
C-sorbitol 
breath test in coeliac disease. We compared the 
13
C-sorbitol breath test to the H2-sorbitol 
breath test in 39 untreated coeliac patients, 40 patients with symptoms compatible with 
coeliac disease referred for evaluation who turned out not to have coeliac disease, and 26 
healthy control subjects. 
The 
13
C- sorbitol breath test and the H2-sorbitol breath test were performed 
simultaneously. Breath samples were gathered every 30 minutes for four hours. Single 
time point variables and combinations of single time point variables were analyzed 
statistically to chose the best test variable(s) for the 
13
C-sorbitol breath test. Optimal 
combined sensitivity and specificity turned out to be obtained with single time point 
measurements at 60 minutes or 90 minutes. The 60 minutes variable was chosen to 
shorten test duration. A diagnostic algorithm dividing patients into high, moderate and 
low risk groups for coeliac disease was proposed. Following the algorithm, sixty-two per 
cent of coeliac patients were detected with 100% specificity. The H2-sorbitol breath test 
had a sensitivity of 71%, a specificity of 46% versus healthy controls, and a specificity of 
25% versus patient controls. 
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5.4 Paper IV 
 
The aim of this study was to evaluate the novel 
13
C-sorbitol breath test for follow-up of 
coeliac disease compared to the H2-sorbitol breath test. Patients with coeliac disease from 
the first study of the 
13
C-sorbitol breath study were invited to participate after 
approximately one year on a gluten-free diet. 27/39 patients repeated the breath tests, and 
25 patients had a new duodenal biopsy. Patients were compared to 40 patients without 
coeliac disease and 26 healthy subjects from the previous study. 
As in the previous study, the 
13
C- sorbitol breath test and the H2-sorbitol breath test were 
performed simultaneously. Breath samples were gathered every 30 minutes for four 
hours.  
The rate of 
13
CO2 excretion increased significantly at all time points before 210 minutes 
in treated versus untreated coeliac patients, but remained lower than in healthy control 
subjects and patient controls at all time points except 30 minutes. This also applied to 
treated patients who had completely normal histological duodenal mucosa after treatment 
with GFD. 20/26 patients had increased 
13
CO2 breath levels after 60 minutes compared to 
their test before treatment. 17/27 patients had a negative H2-sorbitol breath test after 
treatment with GFD. Peak H2 concentrations did not correlate with 
13
C-sorbitol breath 
test results. Mean time to reach peak H2 concentration and mean peak H2 concentration 
did not change after treatment. 
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5.5 Other publications during the PhD programme 
 
Hope HB, Tveito K, Aase S, Messelt E, Utzon P, Skar V. Small intestinal malabsorption 
in chronic alcoholism determined by 13C-D-xylose breath test and microscopic 
examination of the duodenal mucosa. Scand J Gastroenterol. 2010;45(1):39-45. Erratum 
in: Scand J Gastroenterol. 2010 Dec;45(12):1519. 
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6 METHODS 
 
6.1 Study subjects 
 
6.1.1 Patients 
The 
13
C-D-xylose breath test studies had a retrospective design. Patient data were 
collected from the breath test database of 
13
C-D-xylose breath tests and 
14
C-D-xylose 
breath tests at Lovisenberg Diakonale Hospital and Ullevaal University Hospital. Clinical 
files and duodenal biopsies were re-assessed to confirm that the diagnosis of coeliac 
disease was correct. 
In the 
13
C-sorbitol breath test studies patients were included and followed up 
prospectively between 2006 and 2008 in the Department of Gastroenterology at 
Stavanger University Hospital and Lovisenberg Diakonale Hospital. Consecutive patients 
with suspected coeliac disease were included after giving written consent to participate in 
the study. Patients underwent gastroscopy with duodenal biopsies, routine laboratory 
testing and were questioned about gastrointestinal symptoms at inclusion and follow-up. 
Patients who did not have biopsy-confirmed coeliac disease served as patient controls. 
Patients with verified coeliac disease were followed-up after approximately one year.  
 
6.1.2 Healthy control subjects 
Healthy control subjects were recruited from the medical staff and medical students at 
Lovisenberg Diakonale Hospital. Some of the test subjects had performed the breath test 
as controls when the breath test was introduced at Lovisenberg Diakonale Hospital. They 
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had not been tested with serologic markers for coeliac disease. Healthy control subjects 
included after 2004 underwent serological testing for IgA and IgG tissue-
transglutaminase antibodies, and levels within reference values were required to 
participate. All healthy control subjects had normal bowel habits, and had not been 
investigated for gastrointestinal disease in the past. In the 
13
C-sorbitol breath test studies, 
serious illness in the past, having a 1
st
 degree relative with coeliac disease and having 
used antibiotics in the previous month served as additional exclusion criteria. 
 
6.2 Breath test protocols 
All breath tests were performed after an overnight fast. Subjects were quietly seated and 
requested not to eat, drink or smoke during the test period. In the 
13
C-sorbitol breath test 
where hydrogen and methane were also measured, subjects were instructed to ingest a 
meal consisting of fish or chicken and rice and avoid high fibre food the evening before 
the test. Breath was sampled in duplicates at every time point, and mean values of the 
duplicates were used.  
 
6.2.1 
14
C-D-xylose breath test 
1 g D-xylose and 10 μCi 14C-D-xylose, 99% (Amersham, U.K.), were given orally in 500 
ml water as described by Skar et al. [126]. The subjects exhaled through a disposable 
device directly into counting vials. Specific radioactivity of the breath samples was 
determined by liquid scintillation. The results were expressed as percentage of orally 
administered dose 
14
C-D-xylose expired as 
14
CO2 per mmol CO2, corrected for the 
endogenous production of CO2 (9 mmol CO2/kg body weight/h). 
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6.2.2
 13
C-D-xylose breath test 
100 mg 
13
C-1, 2-D-xylose, 99% (Cambridge Isotope Laboratories, Massachusetts, USA), 
and 5 g D-xylose were dissolved in 250 ml tap water. Two end-expiratory breath samples 
were collected via a straw in 12 ml tubes (Labco Limited, High Wycombe, UK) at each 
time point. The 
13
CO2/
12
CO2 ratio in the breath samples was determined by gas 
chromatography (GC) and continuous flow isotope ratio mass spectrometry (IRMS, 
Europe Scientific 20/20, Crewe, UK). The delta-value () between the 
13
CO2/
12
CO2 ratio 
of the samples and the PDB limestone standard was calculated [127], using the following 
formula: 
 = [(Rsa/Rst)-1] x 1000, in which Rsa = 13C/12C in the CO2 of the sample and Rst = 13C/12C 
in the CO2 of the standard. The results were expressed as the percentage of 
13
C-recovery 
per hour (% dose/h). For this calculation the formula of Schoeller et al. was used [128], 
and the CO2 production was assumed to be 300 mmol/m
2
 body surface area per hour. 
Body surface area was calculated by the weight-height formula of Haycock et al [129].  
 
6.2.3
 13
C-sorbitol breath test 
5 g D-sorbitol and 100 mg 
13
C-D-sorbitol, 99% (Aldrich, Milwaukee, USA) dissolved in 
250 ml tap water was given orally. Two parallel end-expiratory breath samples were 
collected via a straw in 12 ml tubes (Exetainers, Labco Limited, High Wycombe, UK) at 
every time point for analysis of 
13
CO2. The 
13
CO2/
12
CO2 -ratio in the breath samples was 
determined by gas chromatography (GC) and continuous flow isotope ratio mass 
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spectrometry (IRMS, Europe Scientific 20/20, Crewe, UK), and expressed as the 
percentage of 
13
C-recovery (% of dose 
13
C/h) for every time point with a similar formula 
as in the  in the 
13
C-D-xylose breath test studies.[128] The CO2 production was assumed 
to be 300 mmol/m
2
 body surface area per hour. Body surface area was calculated by the 
weight-height formula of Haycock et al.[129].  
 
6.2.4 H2-sorbitol breath test 
Duplicate end-expiratory breath samples were collected in 30 ml plastic syringes fitted 
with a T-piece and immediately analyzed for H2 and methane (CH4) by a QuinTron 
Model SC Microlyzer (QuinTron Instrument Company, Milwaukee, USA). 
Concentrations used for calculation were means of duplicate samples. Hydrogen increase 
 20 ppm from the lowest previous level reached prior to an increase counted as a 
positive test. 
 
6.3 D-xylose in plasma and urine 
Blood samples were drawn after one hour, and urine was collected for four hours after 
starting the test with an empty bladder. Duplicate samples of blood and urine were frozen 
at -20 degrees C° before analysis. 
D-xylose was measured in urine by high-performance liquid chromatography (HPLC) 
modified after Larew and Johnson,[130] using an electrochemical detector equipped with 
a gold electrode (ESA coulochem, model 5040, Chelmsford, Massachusetts, USA), a 
Rheodyn injector (Rheodyn inc., California, USA), 20 mikroliter loop and a Supelco C-
611 column with Supelcogel C-611 guarding column (Supelco, Bellefonte, Pennsylvania, 
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USA). Mobil phase was freshly prepared 1mmol/l NaOH (Sigma , St.Louis, Missouri, 
USA) delivered at 1.0 ml/minute isocratic run at 65 degrees C°. Lactose (Sigma) was 
used as internal standard and D-xylose (Sigma) as external standard. Peak heights were 
measured and corrected according to the internal standard. A standard curve was used to 
determine D-xylose concentration. The coefficient of variation was 6%. 
1-h plasma D-xylose levels were measured in duplicate samples by the method of 
Roe and Rice [131]. The coefficient of variation was 10%. 
  
6.4 Statistics 
Statistical analyses were performed using SPSS 14.0, 15.0 or 18.0. Comparison between 
independent groups was made using either independent sample Student’s t-test or one-
way ANOVA for normally distributed variables, and Mann Whitney U test or Kruskal-
Wallis test for continuous variables with skewed distribution. Linear regression was used 
when comparing two continuous variables. Pearson’s chi-square test was used for 
categorical outcome variables. Pearson’s correlation coefficient or Spearman’s 
correlation coefficient was used to estimate correlation between variables. Single time 
point test variables were analyzed by logistic regression. Receiver operating 
characteristic (ROC) curves were used to determine diagnostic accuracy. Findings with p 
values < 0.05 were considered statistically significant. 
 
6.5 Ethics 
The regional ethical committee approved all studies. Informed consent was given by all 
control subjects and by patients included after 2004. 
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7 Discussion 
 
In this first series of studies of 
13
C-labelled breath tests in coeliac disease we found high 
sensitivity for untreated coeliac disease compared to healthy control subjects, and in the 
13
C-sorbitol breath test study, also compared to a patient group with comparable clinical 
symptoms. The latter finding is especially important as it demonstrates the specificity of 
13
C-breath testing in clinical practice. 
In follow-up studies of coeliac patients on a gluten-free diet, we found improved 
breath test results, but treated coeliac patients did not reach healthy control levels. 
Furthermore, we found that the 
13
C-D-xylose breath test has comparable diagnostic 
properties to the 
14
C-D-xylose breath test, and is superior to D-xylose measurements in 
plasma and urine. Finally, when comparing the 
13
C-sorbitol breath test to the H2-sorbitol 
breath test, we showed superiority of the 
13
C-labelled breath test versus H2-testing. 
 
7.1 Strengths and limitations of the studies 
The validity of our findings is strengthened by the fact that we carried out studies with 
three different isotope-labelled breath test protocols with very similar test results. 
Furthermore, many patients were tested before and after treatment with a gluten-free diet, 
which gave us the opportunity to investigate individual changes in breath test results. 
Comparison with other test modalities was performed simultaneously. Thus we could 
exclude intraindividual variance over time as a confounding factor. The prospective 
design of the 
13
C-sorbitol breath test study is considered a major strength of this study, 
especially since we were able to collect both clinical, biochemical and histological data.  
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Other factors than malabsorption such as dysmotility and small intestinal bacterial 
overgrowth can interfere with breath test results. A limitation of our study is that we did 
not carry out additional studies of this. A limitation of the study of D-xylose modalities is 
that we carried out a 4-h xylose excretion test in urine instead of the traditional 5-h D-
xylose excretion test and measured 1-h D-xylose levels in plasma instead of serum. 
Further studies are needed to assess the relationship between mucosal changes in patients 
on a gluten-free diet and breath test results as this was only done in a relatively small 
number of patients in the 
13
C-sorbitol breath test study. 
 
 
7.2 The 
13
C-D-xylose breath test and the 
13
C-sorbitol breath test 
One of the aims in the studies with both isotopes was to decide what is the optimal test 
duration and determine a diagnostic algorithm. We reached different conclusions for the 
two breath tests. In the study of the 
13
C-D-xylose breath test (and the 
14
C-D-xylose breath 
test), we concluded that the highest diagnostic accuracy was achieved combining 
excretion of breath 
13
CO2 in the early and late test phase. The 30min/210 min index was 
proposed. With the 
13
C- sorbitol breath test, we found that a single measurement at 60 
minutes was equally good as a test index combining several variables. How can we 
explain this discrepancy? 
When looking at the breath test curves from the 
13
C-D-xylose breath test and the 
13
C-
sorbitol breath test, a striking difference is apparent in the late test phase. The 
13
CO2 
overshoot in the late test phase in coeliac patients with the 
13
C-D-xylose breath test has 
no equivalent in the 
13
C-sorbitol breath test. This probably explains why adding a late test 
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variable did not increase diagnostic accuracy in the 
13
C-sorbitol breath test study. We do 
not know the reason for the different patterns of 
13
CO2 excretion with the two different 
13
C-substrates. We predict that it has to do with the amount of substrate reaching colon 
and colonic fermentation of the substrates.  
As for the question of which breath test should be preferred in clinical practice, 
several aspects should be considered. The best combined sensitivity and specificity for 
coeliac disease versus healthy controls was found with the 
13
C-D-xylose breath test. The 
classic sprue syndrome of steatorrhoea and malnutrion has become rare, and there has 
been a trend over time for a greater proportion of coeliac patients presenting with 
subclinical/silent coeliac disease and having partial villous atrophy [35, 132]. In line with 
the reports on the changing clinical spectre of coeliac disease, we found that most of the 
patients in our studies had mild if any signs of malabsorption. This change in clinical 
presentation might well explain the reduced sensitivity and specificity we found for D-
xylose testing in plasma and urine compared to early studies of D-xylose tests. Our 
results indicate that the 
13
C-D-xylose breath test is a sensitive test for subtle small 
intestinal malabsorption. This conclusion is supported by the fact that D-xylose levels in 
plasma and urine did not distinguish between treated coeliac disease and healthy control 
subjects, whereas the 
13
C-D-xylose and the 
14
C-D-xylose breath test did.  
The 
13
C-sorbitol breath test had lower optimal combined sensitivity and 
specificity than the 
13
C-D-xylose breath test, but offers a breath test alternative that is 
short (60 minutes), and can be used to stratify patients into high, medium and low risk for 
coeliac disease. Furthermore, the 
13
C-sorbitol substrate is less expensive than 
13
C-D-
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xylose. Finally, the changes in 
13
C-sorbitol breath test results were similar to the changes 
in the 
13
C-D-xylose breath test in coeliac patients after treatment with a gluten-free diet. 
 
7.3 The H2-sorbitol breath test 
Both studies of the H2-breath test showed unsatisfactory diagnostic accuracy with the H2-
sorbitol breath test. The main weakness of the H2-sorbitol breath test was the high 
prevalence of positive breath tests in control groups and in treated coeliac patients. 
The lack of specificity may be specific to the H2-sorbitol breath test, but could also reflect 
a more general problem with the H2-breath tests. Several factors point to the latter 
conclusion. The general use of H2-breath tests might be thwarted by the variability of 
individual gut flora to produce H2 [133-136]. As many as 10% of some populations may 
be non-H2 producers [137-139]. False positive results may also result due to the oral 
bacterial flora and if the subject has failed to adhere to a low fibre diet the day before the 
test [140]. In line with previous studies, we showed that H2-excretion is dependent on the 
presence of methanogenic colonic flora [75, 76, 80]. Methane should also be measured 
and considered when interpreting the H2-breath test. Previous studies of the H2-sorbitol 
breath test have not measured CH4, and we find this a major weakness of these studies. 
The specificity of the H2-sorbitol breath test depends critically on the sorbitol absorption 
capacity in healthy subjects. Further studies may elucidate if a changing the amount and 
concentration of sorbitol in the test solution could improve test specificity. 
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7.4 Pathophysiological considerations 
We have concluded that the 
13
C-breath tests are sensitive markers of small intestinal 
malabsorption. However, other factors than small intestinal damage such as small 
intestinal bacterial overgrowth and dysmotility can also give rise to pathological breath 
test results. Fordtran et al. first demonstrated a relationship between small intestinal 
transit time and extent of D-xylose absorption [92, 97]. Subsequently, Goldstein et al. 
showed that bacteria in the small intestinal lumen can metabolize substantial amounts of 
D-xylose [141]. 
Studies of small bacterial overgrowth in coeliac disease are scarce, but the few studies 
that have been done conclude that small intestinal bacterial overgrowth occurs in a small 
percentage of untreated coeliac patients, and should be suspected in coeliac patients with 
persistent clinical symptoms on a gluten-free diet [142, 143]. We did not carry out any 
experiments to solve this issue. However, the maximum rise in H2 occurred at a late time 
point in the 
13
C-sorbitol breath test and did not differ from the time to reach peak H2 
concentration in controls. If small intestinal bacterial overgrowth had been present in 
coeliac patients, we would expect bacterial metabolism of sorbitol and H2-rise in the early 
test phase before colonic fermentation occurred [123]. The time to reach peak H2 
concentration did not change in coeliac patients after gluten-free diet. If small bacterial 
overgrowth had been present in untreated patients and resolved after treatment, we would 
expect the time to reach H2 peak concentration to change. Furthermore, the shape of the 
isotope-labelled breath test curves did not suggest small intestinal bacterial overgrowth. 
In SIBO, we would expect high rates of 
13
CO2 excretion in the early test phase (first two 
hours) due to bacterial metabolism of the substrate in the small intestine. 
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Several studies have found evidence for gastrointestinal dysmotility in coeliac 
disease [144-146]. We would expect changes in gastric emptying and small intestinal 
transit time to reduce and/or delay small intestinal absorption of the substrate. We cannot 
exclude the possibility that our breath tests reflect dysmotility rather than small intestinal 
malabsorption per se. However, time to reach peak H2 concentration was similar in all 
groups, indicating that there were no significant differences in intestinal transit time 
between groups. Furthermore, Bjarnarson et al. carried out a series of permeability 
studies in coeliac disease with 
51
Cr EDTA absorption test and found very similar results 
to our 
13
C-breath test studies [147]. Since the 
51
Cr-EDTA absorption test consists of a 24 
hours urine excretion test, we can exclude the influence of dysmotility on their results. 
Interestingly, we found similar changes in treated coeliac disease as Bjarnarson et 
al. They reported that although permeability was significantly reduced in treated coeliac 
patients, permeability remained increased compared to healthy control subjects. 
Furthermore, they found that 11/14 patients on gluten-free diet with a completely normal 
mucosa, still had a pathological 
51
Cr EDTA absorption test. Based on their findings they 
raised the intriguing question if patients with coeliac disease have an inherent mucosal 
defect that gives rise to increased permeability even when histological findings have 
resolved. In the 
13
C-sorbitol breath test study we reached the same conclusion.  Breath 
test results remained abnormal compared to healthy control subjects even in patients with 
normal duodenal biopsies according to the Marsh classification. 
 Studies of patients with HIV and studies of patients with alcoholism have showed 
abnormal 
13
C-D-xylose breath tests in the absence of histological small mucosal changes 
[148, 149]. However, when electron microscopy was performed, subtle mucosal changes 
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were detected. We propose that similar findings might be affecting small intestinal 
absorption capacity in coeliac patients on a gluten-free diet. Further studies are needed to 
investigate this issue, and to determine the clinical importance of the findings. 
Bjarnarson et al. found no association between clinical variables in coeliac 
patients and permeability test results [150]. Likewise, there was no correlation between 
clinical symptoms and biochemical signs of malabsorption and breath test results in 
untreated coeliac patients in the 
13
C-sorbitol breath test studies. However, we did find a 
significant association between IgA TGA levels and breath test results in the untreated 
coeliac group. Our findings are in line with a previous study showing lack of correlation 
between clinical presentation and histological changes in coeliac disease [35, 36]. 
 
 
7.5 Clinical considerations 
Malabsorption testing in coeliac disease was developed and studied for many years 
before the development of excellent serological tests for coeliac disease and easy access 
to endoscopic procedures. Although breath testing is probably not useful as a routine test 
in coeliac disease, it might be a valuable additional test in complicated cases, and in 
patients where duodenal biopsies cannot be obtained. The non-invasiveness of the test 
and lack of serious side effects, makes it useful in children and pregnant women. We 
suggest that the 
13
C-breath test protocols should be evaluated also in children with coeliac 
disease. Further studies are needed to decide how breath testing can be of value in follow-
up of coeliac disease. Several researchers have emphasized the importance of early 
diagnosis of coeliac disease. Further studies are needed to determine if isotope labelled 
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breath tests may be of value in the investigation of patients with subtle duodenal 
histological pathology and so called borderline coeliac disease. 
Recent studies show that despite a good clinical response, abnormal endoscopic 
and histopathological appearances persist in the majority of adult patients with coeliac 
disease on a gluten-free diet [151-153]. The clinical significance of these findings is 
uncertain. One study from Finland showed that patients without histological recovery on 
a gluten-free diet were at greater risk of developing complications of coeliac disease such 
as malignancy [154]. The normalization of tissue transglutaminase antibodies does not in 
itself guarantee that the small intestinal villous structure has improved [155]. We do not 
know if the 
13
C-labelled breath tests can be used to determine which patients should be 
followed up with repeated duodenal biopsies, but this question could be addressed in 
further studies.  
 
 
7.6 Conclusion 
Patients with coeliac disease are excellent experimental models for small intestinal 
malabsorption since they can be examined before and after treatment with a gluten-free 
diet. Based on our studies of patients with coeliac disease, we conclude that 
13
C-labelled 
breath tests are sensitive tests for small intestinal malabsorption. 
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Page 1292, Figure 2A 
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Abstract 
Background: We recently developed a 
13
C-sorbitol breath test (
13
C-SBT) as an 
alternative to the H2-sorbitol breath test (H2-SBT) for coeliac disease. In this study we 
compared the diagnostic properties of the H2-SBT and the 
13
C-SBT in follow-up of 
coeliac disease.  
Material and methods: Twenty-seven coeliac patients on a gluten-free diet performed 
the breath tests. All had been tested before treatment in the intial study of the 
13
C-SBT, in 
which 39 untreated coeliac patients, 40 patient controls, and 26 healthy volunteers 
participated. 
5 g sorbitol and 100 mg 
13
C-sorbitol were dissolved in 250 ml tap water and given 
orally. H2, CH4 and 
13
CO2 were measured in end-expiratory breath samples every 30 
minutes for four hours. Increased H2 concentration  20 ppm from basal values was used 
as cut-off for the H2-SBT. 60 minutes values were used as diagnostic index in the 
13
C-
SBT. 
Results: 
13
CO2 levels at 60 minutes increased in 20/26 treated coeliac patients (77%) 
after GFD, but were significantly lower than in control groups. Out of 20 patients who 
had a positive H2-SBT before GFD, 12 had a negative H2-SBT after GFD. Peak H2 
concentrations were not correlated with 
13
C-SBT results. 
Conclusions: The study confirms the sensitivity of a one-hour 
13
C-SBT for small 
intestinal malabsorption. The 
13
C-SBT has superior diagnostic properties compared to the 
H2-SBT in follow-up of coeliac disease. 
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Introduction 
Sorbitol is only partially absorbed in the small intestine, and its malabsorption is dose- 
and concentration-dependent.[1-3] Corazza et al. were the first to show that 
administration of sorbitol at a low dose and concentration to patients with untreated 
coeliac disease resulted in increased excretion of hydrogen (H2) in breath compared to 
healthy controls.[4] Since then a series of studies have suggested high sensitivity of the 
H2-sorbitol breath test (H2-SBT) when screening for coeliac disease in adults.[5-8]  
We recently developed a novel 
13
C-sorbitol breath test, and compared it’s 
diagnostic properties to that of the H2-SBT. We showed that a one-hour 
13
C-sorbitol 
breath test had better sensitivity and specificity for coeliac disease versus healthy controls 
and patient controls than the H2-SBT. A diagnostic algorithm was proposed for the 
13
C-
sorbitol in which  patients were stratified as being at high, moderate or low risk for 
coeliac disease. In this study we aimed to study the diagnostic properties of the 
13
C-
sorbitol breath test in follow up of treated coeliac patients compared to the H2-SBT. 
Coeliac patients who participated in the previous 
13
C-sorbitol study were invited to 
participate. 
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Methods 
Study subjects 
Coeliac patients who had participated in our previous study of the 
13
C-sorbitol breath test 
were invited to perform another breath test after approximately one year on a gluten-free 
diet. Twenty-seven out of 39 patients agreed to participate. Patients underwent 
gastroscopy with duodenal biopsies and routine laboratory testing. The pathologist 
reported the biopsies according to the 1992 Marsh criteria [9], as modified by Oberhuber 
et al. [10]. Serological testing for coeliac disease included measurement of IgA and IgG 
tissue-transglutaminase antibodies (tTGAs, U/ml), IgA gliadin antibodies (Units) and IgA 
levels (g/l). Patients were asked to range their symptoms of diarrhoea, constipation, 
bloating, abdominal pain, nausea, and fatigue on a 4-point Likert scale. A mean item 
score was used to provide a score from 1-4 (no discomfort to severe discomfort) for each 
dimension.  
Patient controls (n = 40) and healthy controls (n = 26) were recruited in the previous 
study of the 
13
C-SBT [11]. Coeliac disease had been excluded by duodenal biopsies in the 
patient control group. The majority of patients in this group suffered from irritable bowel 
syndrome (IBS). 
 
The study was conducted in accordance with the Declaration of Helsinki-Tokyo and 
approved by the regional ethical committee. All subjects gave written consent to 
participate in the study. 
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Breath test protocol 
Test subjects were examined after an overnight fast of at least 10 hours. They were 
instructed to avoid high fibre food, and to consume a meal of rice with fish or meat the 
evening before the test. During the test period, all subjects continued fasting, were quietly 
seated and refrained from smoking., An oral load of 5 g sorbitol and 100 mg 
13
C-D-
sorbitol, 99% (Aldrich, Milwaukee, USA), dissolved in 250 ml tap water, was given 
directly after obtaining four basal breath samples. Breath samples were collected at 30 
minutes intervals for four hours. Duplicate end-expiratory breath samples were collected 
in 30 ml plastic syringes fitted with a T-piece and immediately analyzed for hydrogen 
(H2) and methane (CH4) by a QuinTron Model SC Microlyzer (QuinTron Instrument 
Company, Milwaukee, USA). Concentrations used for calculation were means of 
duplicate samples. Hydrogen increase  20 ppm from the lowest previous values (basal 
values) counted as a positive test.  
Two parallel end-expiratory breath samples were collected via a straw in 12 ml 
tubes (Exetainers, Labco Limited, High Wycombe, UK) at every time point for analysis 
of 
13
CO2. The 
13
CO2/
12
CO2 -ratio in the breath samples was determined by gas 
chromatography (GC) and continuous flow isotope ratio mass spectrometry (IRMS, 
Europe Scientific 20/20, Crewe, UK), and expressed as the percentage of 
13
C-recovery 
(% of dose 
13
C/h) for every time point. The formula of Schoeller et al. was used for this 
calculation.[12] The CO2 production was assumed to be 300 mmol/m
2
 body surface area 
per hour. Body surface area was calculated by the weight-height formula of Haycock et 
al. [13].  
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Statistics 
Data from patient characteristics are outlined in numbers and percentages. Mean with 
standard deviation (SD) or median with range are presented, as appropriate. 
Comparison between independent groups was made using either independent sample 
Student’s t-test or one-way ANOVA for normally distributed variables, and Mann 
Whitney U test or Kruskal-Wallis test for continuous variables with skewed distribution. 
The paired Student’s t-test was used for comparison of variables before and after gluten-
free treatment. Linear regression was used when comparing two continous variables. 
Spearman´s correlation coefficient was used to test for correlation between variables. 
When comparing dichotomised variables, a chi-square test was used. Findings with p 
values < 0.5 were considered significant. All statistical analyses were performed using 
SPSS software package version 18.0 (SPSS Inc., Chicago, Illinois, USA). 
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Results 
Subject characteristics 
The 39 coeliac patients enrolled in the study had Marsh IIIa-c villous atrophy in small 
intestinal biopsies when they were diagnosed with coeliac disease. Twenty-seven patients 
agreed to participate in the follow-up study after treatment with gluten-free diet (median 
duration 12 months, range 6-24 months). Twenty patients had normal duodenal biopsies 
by this time. Four biopsies were classified as Marsh I, one was classified as Marsh IIIa, 
and two patients refused to have a new biopsy. Patient controls were described in detail in 
a previous article [11]. Patients and healthy control characteristics are summarised in 
table I. 
 
H2-sorbitol breath test results 
Positive H2-sorbitol breath tests were obtained in 27/38 untreated coeliac patients (71%). 
After gluten-free diet, 17/27 coeliac patients (63%) had a negative H2-sorbitol breath test, 
while 10/27 coeliac patients (37%) had a positive H2-sorbitol breath test (Figure 1). One 
of the intital H2-sorbitol breath tests from the 27 coeliac patients tested twice was 
discarded due to technical problems. Twenty of the remaining 26 breath tests were 
positive before GFD. After GFD, twelve of these patients had a positive H2-sorbitol 
breath test (60%), and eight were negative (40%). Out of the six coeliac patients who had 
negative H2-sorbitol breath tests before treatment, five also had a negative test after GFD, 
but one patient had a positive breath test after GFD. As shown in the previous study, 
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30/40 patient controls (75%), and 14/26 healthy subjects (54%) had a positive H2-sorbitol 
breath test. 
Mean peak H2 concentration was 37 ± 37 ppm in coeliac patients, 25 ± 28 ppm in treated 
coeliac patients, 42 ± 32 ppm in patient controls, and  28 ± 24 ppm in healthy controls. 
Mean time to reach peak H2 concentration was 188 ± 49 min in coeliac patients, 190 ± 48 
min in treated coeliac patients, 178 ± 58 min in patient controls, and 190 ± 49 min in 
healthy controls. Peak H2 concentration differed significantly between treated coeliac 
patients and patient controls (p = 0.01), but not between other groups. Time to reach peak 
H2 concentration did not differ significantly between groups.  
 
13
C-sorbitol breath test results 
Mean breath 
13
CO2 levels were significantly higher in the 26 treated coeliac patients (one 
test was discarded due to technical problems) than in untreated coeliac patients at all time 
points before 240 minutes, and significantly lower in treated coeliac patients than in 
control subjects without coeliac disease at all time points exept 30 minutes (Figure 2). On 
an individual level, 
13
CO2 levels at 60 minutes increased in 20/26 treated patients (77%).  
In our previous study of the 
13
C-sorbitol breath test, 60 minutes 
13
CO2 levels in 
breath were chosen as the diagnostic test variable, and the following diagnostic algorith 
proposed:  Excreted dose of 
13
C/h at 60 minutes: < 2% = high probability for coeliac 
disease, 2-4% = moderate probability for coeliac disease, and > 4% = low probability for 
coeliac disease. Sixteen of the treated coeliac patients (59%) had a 60 minutes 
13
CO2 
level < 2% before treatment. 
13
CO2 levels increased above the 2% cut-off in 12/16 
patients (75%, Figure 3). The patient with the lowest level of exhaled 
13
CO2 at 60 minutes 
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had Marsh 3a villous atrophy in the control biopsy performed after GFD. The other three 
patients with excreted dose of 
13
C/h at 60 minutes <2% had normal control duodenal 
biopsies.  Seventeen treated patients (63%) excreted between 2-4% of ingested dose of 
13
C after 60 minutes, and five patients (19%) had 
13
CO2 levels > 4% of ingested dose.  
 
Comparison of breath tests and correlation with clinical variables  
No significant association was found between peak H2 concentrations and 
13
CO2 values at 
60 minutes in any of the groups. In the coeliac group there was an inverse association 
between 
13
CO2 values at 60 minutes and age (p = 0.037), which was not found in the 
other groups.  Age was inversely associated with peak H2 concentration in the treated 
coeliac group (p = 0.007), but not in the other groups. Duration of gluten-free diet was 
not significantly associated with 
13
CO2 values at 60 minutes or to peak H2 concentrations. 
IgA tTGA levels were inversely associated to 60 minutes 
13
CO2 values (p = 
0.025) in the untreated coeliac group, but there was no association in the treated coeliac 
group. Peak H2 concentrations were not associated to IgA tTGA levels in any of the 
groups. In the coeliac group, peak H2 concentrations increased significantly with 
increasing severity of duodenal lesions, classified from Marsh IIIa to Marsh IIIc (p < 
0.001). IgA tTGA levels increased and 
13
CO2 excretion rates at 60 minutes decreased 
from Marsh IIIa to Marsh IIIc, but these associations did not reach significance.  
Symptom scores decreased significantly for all symptom variables except bloating 
after GFD (Table 2). The 60 minutes variable after GFD was inversely associated to 
fatigue after GFD (p = 0.039), but not to other symptom scores.  
 10 
S-folate and s-vitamin B12 increased significantly after GFD (s-folate: mean 
difference 4,44 nmol/L, p = 0.001, and vitamin B12: mean difference 55,3 pmol/L, p < 
0.001). S-ferritin, but not b-haemoglobin (b-Hb), increased significantly in both gender 
after GFD (women: mean difference 20,1 mikrogram/L, p=0.038, men: mean difference 
71,2 mikrogram/L, p= 0.001). In the treated coeliac group, 
13
CO2 excretion rates at 60 
minutes were not associated with levels of s-folat, s-vitamin B12, b-Hb and s-ferritin. 
Peak H2 concentration in the treated group was positively associated to b-Hb in men (n = 
11, p = 0.018), but not in women. There was no association between peak H2 
concentration and s-folat, s-vitamin B12 or s-ferritin in the treated group.  
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Discussion  
This first study of the 
13
C-sorbitol breath test in patients with treated coeliac disease, 
confirms the sensitivity of the 
13
C-sorbitol breath test for small intestinal malabsorption. 
Seventy-seven percent of coeliac patients tested both before and after gluten-free diet 
increased their 
13
C-sorbitol breath test score after GFD. The H2 breath test with a cut-off 
level at 20 ppm had a sensitivity of 63% and a specificity of 71% for treated versus 
untreated coeliac patients.  
The improvement in breath test results was accompagnied by normalization of 
duodenal biopsies in all but four patients, significant decline in symptom scores and 
increased levels of s-ferritin, s-folate and s-vitamin B12. Generally, laboratory results 
were not associated with breath test results, as in our previous study of the 
13
C-sorbitol 
breath test and the H2-sorbitol breath test in untreated coeliac disease. That increasing 
peak H2 concentration was associated with increasing b-Hb in treated male coeliac 
patients was unexpected, and may be due to a type I statistical error. 
 There was a significant association between peak H2 concentration and increasing 
histopathology in the untreated coeliac group. A parallell, but non-significant trend was 
seen for 
13
CO2 excretion rates at 60 minutes. Furthermore, a non-significant increase in 
IgA tTGA levels from Marsh IIIa-IIIc was seen. Our results are in line with studies by 
Tursi et al., who found higher serum values of IgA tTGA with increasing histopathology 
in untreated coeliac disease, and a strict correlation between H2-sorbitol breath test cut-
off values (in ppm and minutes) and histological lesions [14, 15]. However, 
13
CO2 
excretion rates remained lower in treated coeliac patients with normal duodenal biopsies 
than healthy controls and patients without coeliac disease. Furthermore, 40% of the 
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patients who had a positive H2-sorbitol breath test before GFD, also had a positive H2-
sorbitol breath test after GFD. These results are in line with a report from Bjarnason et al. 
who, using the 
51
Cr EDTA absorption test, found persistent small intestine permeability 
in treated coeliac patients despite small intestinal mucosal healing [16]. Likewise, studies 
of patients with HIV and diarrhoea [17], and a study of patients with high alcohol 
consumption and diarrhoea [18], have shown 
13
C-xylose breath test results compatible 
with small intestinal malabsorption despite light microscopically normal duodenal 
mucosa. Electron microscopic studies of the two latter patient groups revealed subtle 
architectural damage of the small intestinal mucosa. Similar minor small intestinal 
histopathology may persist also in treated coeliac patients. We also cannot exclude, as 
Bjarnason et al. proposed, the possibility of an inherent increase in small intestinal 
mucosal permeability in coeliac patients. Further studies are needed to investigate this 
issue and to determine the clinical importance of the findings. 
 In a kinetic study of D-xylose absorption, Breiter et al. found that total breath H2 
excretion was not correlated with the extent of D-xylose absorption [19]. Likewise, we 
could not show any correlation between the results of the 
13
C-sorbitol breath test and 
peak H2 excretion. H2 production in the large intestine due to small intestinal 
malabsorption of carbohydrate has been showed to vary considerably between 
individuals, and also interindividually over time [20-22]. This may explain the lower 
sensitivity of the H2-sorbitol breath test compared to the 
13
C-sorbitol breath test, and also 
the lack of correlation between the two breath tests.  Our previous study of the H2-
sorbitol breath test showed very low specificity of the H2-sorbitol breath test for untreated 
coeliac disease versus patients with gastrointestinal symptoms without coeliac disease 
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and healthy control subjects [11]. The present study shows that the H2-sorbitol breath test 
is also not ideally suited for follow-up of coeliac disease. 
Some studies have showed changes in intestinal motility after treatment of coeliac 
disease with GFD [23-25]. Time to reach peak H2 concentration was unchanged after 
GFD in our study. If there had been a significant change in motility with a gluten-free 
diet, we would expect a difference in rate of delivery of sorbitol to the large intestine and 
a change in time to reach peak H2 concentration. Our study did not provide such 
evidence, and we believe that the changes in 
13
CO2 excretion rate after GFD is mainly 
due to increased small intestinal sorbitol absorption capacity. 
 As expected, coeliac patients reported reduced gastrointestinal symptoms after 
GFD. Interestingly, the fatigue score after GFD was inversely associated to 
13
C-sorbitol 
breath test results. Studies of patients with untreated coeliac disease have not showed any 
correlation between symptom presentation and severity of mucosal damage [26]. Further 
studies are needed to examine the possibility of a correlation of fatigue in patients with 
treated coeliac disease and persistently reduced small intestinal absorption capacity.  
 In conclusion, we recommend that the H2-sorbitol breath test be abandoned due to 
low specificity versus patients with other gastrointestinal disorders such as IBS, and 
versus healthy controls. The novel 
13
C-sorbitol breath test shows superior diagnostic 
properties to the H2-sorbitol breath test for diagnosis and follow-up of coeliac disease. 
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Table I. Clinical characteristics of study patients. 
 
 Untreated 
coeliac patients, 
n = 39 
Treated coeliac 
patients, n = 27 
Patient controls, 
n = 40 
Healthy control 
subjects, n = 26 
Age, median 
(range) 
36 (19-82) 44 (20-83) 29 (17-65) 30 (22-60) 
Female/Male 24/15 15/12 26/14 18/8 
BMI, mean (SD) 22.9 (3.6) 23.7 (3.4) 22.3 (2.8) 22.3 (2.5) 
Small bowel 
histology: 
Marsh 0 
Marsh I 
Marsh IIIa 
Marsh IIIb 
Marsh IIIc 
 
 
0 
0 
15 
12 
12 
 
 
20 
4 
1 
0 
0 
 
 
36 
4 
0 
0 
0 
 
 
 
 
 
IgA tTGA > 5U/ml  
IgA tTGA 2-5U/ml 
IgA tTGA < 2U/ml 
36  
0 
3 
2 
6 
19 
5 
1 
0 
0 
0 
26 
BMI, body mass index, kg/m
2
; IgA tTGA, IgA tissue transglutaminase antibody 
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Table II. Symptoms graded 1-4 (none-mild-moderate-severe) in coeliac patients tested 
twice. 
 
Symptoms n Untreated coeliac 
patients 
Mean (SD) 
 Treated coeliac 
patients 
 Mean (SD) 
 
p-value 
 
Diarrhoea 
Bloating 
Abdominal pain 
Nausea 
Constipation 
Fatigue 
 
27  
22 
26 
26 
27 
20 
 
2.7 (1.0) 
2.3 (0.9) 
2.9 (1.1)  
3.3 (1.1) 
2.9 (1.3) 
2.7 (1.1) 
 
 
 
 
 
 
 
 
1.6 (1.0) 
2.1 (1.1) 
1.4 (0.7) 
1.2 (0.5) 
1.2 (0.5) 
1.8 (1.1) 
 
0.001 
0.55 
0.001 
< 0.001 
< 0.001 
0.03 
 
n; number of individuals in whom the paired t-test was performed. 
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